Multiple Myeloma: A New Treatment Option for Newly Diagnosed, Transplant-Ineligible Patients

This supplement is sponsored by Janssen Biotech, Inc.


Saad Z. Usmani, MD, FACP, discusses a new treatment option for newly diagnosed, transplant-ineligible patients with multiple myeloma.

Article includes:

  • An important option for patients with multiple myeloma
  • Details on the phase 3 trial
  • Efficacy and safety profile




Next Article: